WednesdayJun 05, 2024 2:34 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has announced that management will present at the Emerging Growth Conference. Clene’s presentation is slated to begin at 2:20 p.m. on June 12, 2024, and include a corporate presentation with questions and-answers. Interested parties can visit https://ibn.fm/A217J to register for and view the webcast, which will also be available on the Events section of the Clene website. A replay of the presentation will be available as detailed…

Continue Reading

WednesdayJun 05, 2024 12:51 pm

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Receives $1M from CEO to Support Company’s Efforts to ‘Lead the Way’ to More Efficient Healthcare System

HealthLynked (OTCQB: HLYK), a leader in personalized healthcare and patient-centric services, has received $1 million in financing from CEO Dr. Michael Dent, which will provide additional capital so the company can expand its offerings and accelerate its growth. A visionary in the healthcare industry, Dent has been at the helm of HealthLynked as it has developed services designed to enhance the patient experience and improve healthcare outcomes. HealthLynked services include online scheduling for doctors nationwide, personal medical record storage, telemedicine, nurse chat, a rewards points program, an e-commerce platform for more than 15,000 name-brand medical supplies, comanagement of family members'…

Continue Reading

WednesdayJun 05, 2024 10:14 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Event Spotlighting Lead Drug Candidate

Annovis Bio (NYSE: ANVS), a late-stage, clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”) will host an investor webcast. According to the announcement, during the webcast, Annovis Bio officials will discuss recent advancements in the development of Buntanetap, the company’s lead drug candidate, as well as strategic plans for upcoming clinical trials and an overview of the company’s progress along with its future direction. The call is slated for June 11, 2024, at 4:30 p.m. ET. Buntanetap has been formulated to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including…

Continue Reading

MondayJun 03, 2024 3:49 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Releases Q1 2024 Quarterly Report

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, is reporting its first-quarter 2024 revenues. According to the report, the company saw revenues of $408,532 while also strengthening its balance sheet with the completion of an $8.4 million private placement involving existing and new shareholders; shares for the placement were offered at $4 per share. Nutriband also reported a cash position of $8,347,739. In the report, the company observed that it been focused on using penetration pricing to gain a foothold. “Meanwhile in Q1, the company has made further advancements in its development of AVERSA, and it is maintaining…

Continue Reading

MondayJun 03, 2024 3:22 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Reverse Stock Split

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock, effective at 4:01 p.m. ET on June 4, 2024. According to the update, beginning on June 5, 2024, the company’s common stock will continue to trade on the Nasdaq Capital Market on a split adjusted basis under the trading symbol CNSP, but will trade under the following new CUSIP number: 18978H300. The move is primarily intended to increase CNSP’s share trading price and bring…

Continue Reading

FridayMay 31, 2024 3:46 pm

BioMedNewsBreaks — Biomerica Inc. (NASDAQ: BMRA) Announces Agreement in $5.5M At-the-Market Offering

Biomerica (NASDAQ: BMRA), a biomedical technology company that develops, patents, manufactures and markets advanced diagnostics and therapeutic products, has entered into an at-market issuance sales agreement with EF Hutton LLC and R.F. Lafferty & Co. Inc. According to the company, the agreement is related to BMRA common stock shares. The company filed a prospectus supplement on May 10, 2024. EF Hutton is serving as sales agent to Biomerica in connection with the $5.5 million at-the-market offering. “In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock pursuant to this prospectus having…

Continue Reading

FridayMay 31, 2024 2:25 pm

BioMedNewsBreaks — Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. “The company’s AVERSA(TM) can be incorporated into any transdermal patch and includes aversive agents to prevent misuse and accidental exposure to drugs with abuse potential, specifically opioids. AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia… Nutriband…

Continue Reading

WednesdayMay 29, 2024 1:42 pm

BioMedNewsBreaks — Predictive Oncology Inc. (NASDAQ: POAI) CEO to Participate at Upcoming BIO International Convention 2024

Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, will be spotlighted at next month’s BIO International Convention 2024. The conference is scheduled for June 3–6, 2024, in San Diego. According to the announcement, Predictive Oncology CEO Raymond Vennare will be presenting a company overview at the gathering. His presentation, titled “Novel AI Driven Insights to Guide Early Drug Discovery,” is slated to begin at 6:45 EDT on June 3, 2023. “We are very pleased to participate in this year’s Bio International Convention, which is the premier gathering of biopharmaceutical stakeholders from around the world,” said…

Continue Reading

WednesdayMay 29, 2024 11:23 am

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Submission of Clinical Trial Protocol for Unbuzzd(TM) Study

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a clinical trial protocol to assess the safety and efficacy of Unbuzzd(TM) in healthy volunteers. The clinical trial protocol for the METAL-2 trial will be reviewed by the U.S. institutional review board. After receiving approval, the company will begin recruiting healthy volunteers for the study, which is designed to evaluate the ability of Unbuzzd to help alleviate the effects of acute alcohol intoxication. “We are thrilled that we have reached…

Continue Reading

TuesdayMay 28, 2024 2:32 pm

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Launches Innovative, AI-Powered Chat Function

HealthLynked (OTCQB: HLYK), a leading innovator in healthcare technology, today unveiled its new AI-powered chat function designed to assist patients in finding healthcare providers across the country. The new AI chat bot will significantly enhance the effectiveness of the HealthLynked Concierge Team, reducing wait times and offering 24/7 service to users. The advanced feature will provide instant answers to customer questions as well as assist in locating healthcare providers by name, specialty or location. “Our new AI chat function is a testament to our commitment to leveraging cutting-edge technology to improve healthcare accessibility,” said Dr. Michael Dent, CEO of HealthLynked.…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050